BlockerLife

Health and family

Experimental Lp(a) drug lowered blood levels but did not prevent cardiovascular complications

An experimental drug sharply reduced a blood particle linked to heart attacks and strokes, but did not reduce cardiovascular complications in a major study, researchers reported on November 7, 2026.

The study enrolled 8,350 adults who already had heart disease. Participants received either a placebo or pelacarsen, a drug designed to lower lipoprotein(a), or Lp(a). Pelacarsen reduced Lp(a) levels by about 78%, but after five years, that reduction had not translated into fewer cardiovascular complications.

“I was shocked. I had high hopes for success,” said Steven Nissen, the Cleveland Clinic cardiologist who led the study. He presented the initial findings at an American Heart Association meeting in Chicago; further details were published in the New England Journal of Medicine and NEJM Evidence.

Elevated Lp(a) has long been associated with cardiovascular risk. Nissen said about 20% of the global population—roughly a billion people—have elevated levels. The study tested whether lowering Lp(a) could help people who remain at risk despite efforts to control factors such as cholesterol and blood pressure.

The findings do not establish why pelacarsen failed to improve outcomes. Researchers raised several possibilities: treatment might need to begin earlier or continue longer; people with higher Lp(a) levels might respond differently; or the result might be specific to pelacarsen. They also said the study raises questions about whether elevated Lp(a) directly causes heart attacks and strokes or is a marker of another risk.

Novartis, which sponsored the study, had announced in October 2026 that it had not met its goals, without releasing specifics at the time. Other experimental Lp(a)-lowering drugs were still being tested as of the November 2026 report. The pelacarsen result therefore does not settle whether a different approach could reduce cardiovascular risk.